Plasma concentrate
Fibrogammin P (CSL Behring), was used a source of human Factor XIII heterotetramer. FXIII was purified using gel filtration chromatography on a
Superdex 200 10/300 GL column (GE Healthcare). Briefly, the column was equilibrated with running buffer (30 mM Tris, 150 mM NaCl, pH 7.4),
Fibrogammin P was loaded and fractions were eluted. Fractions corresponding to the molecular weight of FXIII heterotetramer (~320 kDa), were collected and sequentially re-purified thrice until a single, homogenous, monodispersed peak was observed. For each set of
in vitro activation experiments, 25 μg of purified FXIIIA
2B
2 dissolved in 20 mM Tris, 120 mM NaCl, pH 7.4 buffer was incubated with 46.2 U/mL of
thrombin (Sigma, USA), at different concentrations of calcium chloride (0 mM, 1 mM, 2 mM, 5 mM, 10 mM and 25 mM), for 60 minutes at 30 degrees. Reaction product was filtered and resolved using a
Superdex 200 PC 3.2/30 (GE Healthcare) analytical column. Peaks from samples loaded at different calcium ion concentrations were collected and analyzed on
Native PAGE (Life technologies, Germany). The observed bands were analyzed and confirmed for the presence of FXIIIA and FXIIIB by Mass Spectrometry (see
Supplementary Data).
Gupta S., Biswas A., Akhter M.S., Krettler C., Reinhart C., Dodt J., Reuter A., Philippou H., Ivaskevicius V, & Oldenburg J. (2016). Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective. Scientific Reports, 6, 30105.